Patient receives groundbreaking NK cell therapy for glioblastoma

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium https://lnkd.in/dWGjYPdQ This study systematically reviewed 119 publications on neoadjuvant therapy in renal cell carcinoma (RCC) to evaluate how pathological response is currently assessed and reported. The analysis revealed that only 4% of studies detailed their response assessment methods, and just 7% employed quantitative measures, highlighting a lack of standardization. To address this, an international expert workshop at the Netherlands Cancer Institute in 2024 developed consensus recommendations for tissue preparation and response reporting. The proposed guidelines advocate for standardized specimen sampling, quantification of residual viable tumor in 10% intervals with measurement of greatest linear extent, and inclusion of clinical treatment details. These standardized methods aim to enable consistent evaluation of pathological response in RCC, facilitating research into its correlation with survival outcomes and paving the way toward uniform reporting in future clinical studies. #KidneyCancer James Blackmur  Femke Burgers  Michelle Hirsch Payal Kapur  Rohit Mehra  Priya Rao  Sabina Signoretti  Grant Stewart james jones

These standardized methods aim to enable consistent evaluation of pathological response in RCC, facilitating research into its correlation with survival outcomes and paving the way toward uniform reporting in future clinical studies. #KidneyCancer

New study maps tumor cell types in TNBC and finds a stem‑like, basoluminal‑loss phenotype linked to rapid recurrence, plus an inflamed CD8+ T cell group with better prognosis and immunotherapy response — proposing five prognostic subtypes to guide treatment 🧬 #BreastCancer #TNBC #PrecisionOncology https://lnkd.in/e2ymGHah

The “immunotherapy resistant” stroma may finally have a weakness. This new study introduces [¹⁷⁷Lu]Lu-DUNP19, a first-in-class LRRC15-targeted radio-immunotheranostic that hits both tumor cells and the LRRC15⁺/TGFβ stroma that drives checkpoint resistance. 🔬 In preclinical models (osteosarcoma, glioblastoma, colorectal, breast): ・[¹⁷⁷Lu]Lu-DUNP19 showed picomolar binding affinity, tumor-specific uptake, and durable regressions. ・Therapy depleted the LRRC15⁺/TGFβ stromal signature, dismantling a major barrier to T-cell infiltration. ・When combined with PD-1 + CTLA-4 blockade, the approach converted “cold” tumors into immune-responsive lesions, achieving durable cures without added toxicity. 📊 Molecular profiling revealed apoptosis induction, MYC/E2F suppression, and DNA repair stress, pointing to rational combinations with DDR inhibitors and immuno-oncology agents. With a clear biomarker strategy (LRRC15-PET for patient selection, transcriptomic readouts for response), this program follows the Pluvicto playbook but extends it into stroma-rich, ICI-refractory cancers. 👉 Full study:https://lnkd.in/gm_QFyQZ 👉 I shared more thoughts in my Medium article: "Targeting LRRC15 with Radiotheranostics: A Dual Attack on Tumor Cells and Stroma " https://lnkd.in/gC9wsgGt ✍️ Disclaimer: These are my personal views, and I have no conflicts of interest (COI). This article does not constitute medical advice, and this post should not be interpreted as investment advice.

Prior to biologics like Remicade and Humira (or when those drugs failed to work), we treated ulcerative colitis with a small dose of a leukemia drug to lower B-cell activity. When clinical trails using CAR-T for autoimmune disease started, my first thought was, when can we start using it for inflammatory bowel diseases? This is great news. Full remission of a treatment resistant case.

🧬 CAR-T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges. Gastrointestinal cancers remain a leading cause of mortality, with poor responsiveness to immunotherapy. The remarkable success of CAR T cells in hematologic malignancies has generated strong interest in their application to GI cancers, but barriers persist: tumor architecture, immune suppression, scarcity of tumor-selective antigens, antigenic heterogeneity and metabolic imbalance. Ongoing clinical trials, together with innovative CAR T designs armed with adjuvants to sustain activity in hostile tumor microenvironments, are paving the way for more effective strategies in solid tumors. 📖 Nature Reviews Gastroenterology & Hepatology DOI 👉🏻 https://lnkd.in/e93Dtisf #CánCare #cancer #oncology #immunotherapy #CAR #GIcancer #biomarkers #solidtumors #precisionmedicine

🔎 Another important study has consolidated our current personalised approach in Burjeel Cancer Institute | BCI: ➡️ Repeat biomarker testing is warranted when negative in the upfront biopsy and in post-NACT residual disease. ➡️ Re-evaluation of positive markers should only be considered if there is a clear shift in morphology—for example, the emergence of a metaplastic carcinoma component in a tumour previously diagnosed as luminal. This approach is also indirectly reinforced by both the College of American Pathologists (CAP) and the Royal College of Pathologists, ensuring that our reporting remains both evidence-based and clinically impactful. 💡 These nuances are crucial in guiding oncologists towards the most appropriate therapeutic strategy, avoiding unnecessary repetition, while also not missing actionable changes. #BreastCancer #Pathology #NACT #Biomarkers #Oncology #CancerCare https://lnkd.in/dWBxuig2

Logan Health is proud to announce the addition of PLUVICTO, a groundbreaking targeted treatment for prostate cancer, now available at Logan Health Medical Center. Logan Health becomes only the third health system in Montana to offer this innovative therapy, joining facilities in Helena and Billings. Unlike traditional chemotherapy, which affects the entire body, PLUVICTO is a targeted treatment designed to attack prostate cancer cells directly. This means patients often experience fewer side effects and generally feel less sick compared to systemic chemotherapy. The therapy is also quick and convenient, administered through a short intravenous infusion in a comfortable outpatient setting. https://lnkd.in/gjAwq5c9

🔬 New Study Reveals How Breast Cancer’s Tumor Microenvironment Evolves During Treatment Breast tumors are not just malignant cells; they are ecosystems of immune cells, fibroblasts, blood vessels, and extracellular matrix (ECM). A new study using single-cell and spatial omics has shown how these components evolve during chemotherapy, reshaping treatment response, relapse risk, and future therapy opportunities. Key insights include: ✅ Chemotherapy can both boost and suppress immune responses ✅ Cancer-associated fibroblasts remodel ECM, creating treatment barriers ✅ Endothelial cells reshape vasculature, forming therapy-resistant niches ✅ Spatial “cellular neighborhoods” predict patient outcomes ✅ Future therapies may need to co-target the TME with immunotherapy or antifibrotic drugs This research marks a paradigm shift in oncology: from treating tumors as static entities to viewing them as dynamic ecosystems. By integrating tumor microenvironment (TME) profiling into care, oncologists can move closer to precision oncology that adapts with each patient’s tumor. At Onco Life Centre Malaysia, we are committed to advancing patient-centered cancer care informed by the latest breakthroughs in tumor biology and therapy. Read the full article here: 🔗 https://lnkd.in/gPaizyrD #BreastCancerResearch #Oncology #PrecisionMedicine

Canary Oncoceutics is dedicated to revolutionizing cancer care with advanced diagnostic solutions. 🔬 Our latest blog post dives deep into a critical topic: the different types of Prostate-Specific Antigen (PSA) tests. 📖 Did you know that while the standard total PSA test is a common screening tool, its limitations can leave questions unanswered? 🤔 Our article explores how advancements like free PSA, PSA velocity, and PSA density offer a more personalized approach to prostate cancer detection. 🧬 Learn how these tests provide doctors with deeper insights, moving us closer to more precise and effective patient care. ⚕️ https://lnkd.in/gipZeiNf #ProstateCancer 🎗️ #Diagnostics 🧪 #PrecisionMedicine 🎯 #CancerCare 🩺 #Genomics 🧬 #CanaryOncoceutics 🚀 #HealthTech 💻 #MedicalInnovation 💡